Literature DB >> 33743799

Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults.

Wesley H Self1,2, Thomas G Stewart3, Allison P Wheeler4, Wissam El Atrouni5, Amanda J Bistran-Hall6, Jonathan D Casey7, Vince D Cataldo8, James D Chappell9, Claudia S Cohn10, Jessica B Collins6, Mark R Denison9, Marjolein de Wit11, Sheri L Dixon6, Abhijit Duggal12, Terri L Edwards6, Magali J Fontaine13, Adit A Ginde14, Michelle S Harkins15, Thelma Harrington16, Estelle S Harris17, Daanish Hoda18, Tina S Ipe19, Stuti J Jaiswal20, Nicholas J Johnson21, Alan E Jones22, Maryrose Laguio-Vila23, Christopher J Lindsell3, Jason Mallada24, Manoj J Mammen25, Ryan A Metcalf26, Elizabeth A Middleton17, Simon Mucha12, Hollis R O'Neal27, Sonal R Pannu28, Jill M Pulley6, Xian Qiao29, Jay S Raval30, Jillian P Rhoads6, Harry Schrager31, Carl Shanholtz16, Nathan I Shapiro32, Stephen J Schrantz33, Isaac Thomsen9, Krista K Vermillion6, Gordon R Bernard6,7, Todd W Rice6,7.   

Abstract

BACKGROUND: Convalescent plasma is being used widely as a treatment for coronavirus disease 2019 (COVID-19). However, the clinical efficacy of COVID-19 convalescent plasma is unclear.
METHODS: The Passive Immunity Trial for Our Nation (PassITON) is a multicenter, placebo-controlled, blinded, randomized clinical trial being conducted in the USA to provide high-quality evidence on the efficacy of COVID-19 convalescent plasma as a treatment for adults hospitalized with symptomatic disease. Adults hospitalized with COVID-19 with respiratory symptoms for less than 14 days are eligible. Enrolled patients are randomized in a 1:1 ratio to 1 unit (200-399 mL) of COVID-19 convalescent plasma that has demonstrated neutralizing function using a SARS-CoV-2 chimeric virus neutralization assay. Study treatments are administered in a blinded fashion and patients are followed for 28 days. The primary outcome is clinical status 14 days after study treatment as measured on a 7-category ordinal scale assessing mortality, respiratory support, and return to normal activities of daily living. Key secondary outcomes include mortality and oxygen-free days. The trial is projected to enroll 1000 patients and is designed to detect an odds ratio ≤ 0.73 for the primary outcome. DISCUSSION: This trial will provide the most robust data available to date on the efficacy of COVID-19 convalescent plasma for the treatment of adults hospitalized with acute moderate to severe COVID-19. These data will be useful to guide the treatment of COVID-19 patients in the current pandemic and for informing decisions about whether developing a standardized infrastructure for collecting and disseminating convalescent plasma to prepare for future viral pandemics is indicated. TRIAL REGISTRATION: ClinicalTrials.gov NCT04362176 . Registered on 24 April 2020.

Entities:  

Keywords:  COVID-19; Clinical trials; Neutralizing antibodies; Passive immunity; Randomized controlled trial; SARS-CoV-2: convalescent plasma

Mesh:

Year:  2021        PMID: 33743799      PMCID: PMC7980732          DOI: 10.1186/s13063-021-05171-2

Source DB:  PubMed          Journal:  Trials        ISSN: 1745-6215            Impact factor:   2.279


  30 in total

Review 1.  Likelihood methods for measuring statistical evidence.

Authors:  Jeffrey D Blume
Journal:  Stat Med       Date:  2002-09-15       Impact factor: 2.373

2.  New mutations raise specter of 'immune escape'.

Authors:  Kai Kupferschmidt
Journal:  Science       Date:  2021-01-22       Impact factor: 47.728

3.  ResearchMatch: a national registry to recruit volunteers for clinical research.

Authors:  Paul A Harris; Kirstin W Scott; Laurie Lebo; Niknik Hassan; Chad Lightner; Jill Pulley
Journal:  Acad Med       Date:  2012-01       Impact factor: 6.893

4.  Early High-Dose Vitamin D3 for Critically Ill, Vitamin D-Deficient Patients.

Authors:  Adit A Ginde; Roy G Brower; Jeffrey M Caterino; Lani Finck; Valerie M Banner-Goodspeed; Colin K Grissom; Douglas Hayden; Catherine L Hough; Robert C Hyzy; Akram Khan; Joseph E Levitt; Pauline K Park; Nancy Ringwood; Emanuel P Rivers; Wesley H Self; Nathan I Shapiro; B Taylor Thompson; Donald M Yealy; Daniel Talmor
Journal:  N Engl J Med       Date:  2019-12-11       Impact factor: 91.245

5.  A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19.

Authors:  Jens D Lundgren; Birgit Grund; Christina E Barkauskas; Thomas L Holland; Robert L Gottlieb; Uriel Sandkovsky; Samuel M Brown; Kirk U Knowlton; Wesley H Self; D Clark Files; Mamta K Jain; Thomas Benfield; Michael E Bowdish; Bradley G Leshnower; Jason V Baker; Jens-Ulrik Jensen; Edward M Gardner; Adit A Ginde; Estelle S Harris; Isik S Johansen; Norman Markowitz; Michael A Matthay; Lars Østergaard; Christina C Chang; Victoria J Davey; Anna Goodman; Elizabeth S Higgs; Daniel D Murray; Thomas A Murray; Roger Paredes; Mahesh K B Parmar; Andrew N Phillips; Cavan Reilly; Shweta Sharma; Robin L Dewar; Marc Teitelbaum; Deborah Wentworth; Huyen Cao; Paul Klekotka; Abdel G Babiker; Annetine C Gelijns; Virginia L Kan; Mark N Polizzotto; B Taylor Thompson; H Clifford Lane; James D Neaton
Journal:  N Engl J Med       Date:  2020-12-22       Impact factor: 91.245

6.  COVID-19 vaccines: the pandemic will not end overnight.

Authors: 
Journal:  Lancet Microbe       Date:  2020-12-18

7.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.

Authors:  Lindsey R Baden; Hana M El Sahly; Brandon Essink; Karen Kotloff; Sharon Frey; Rick Novak; David Diemert; Stephen A Spector; Nadine Rouphael; C Buddy Creech; John McGettigan; Shishir Khetan; Nathan Segall; Joel Solis; Adam Brosz; Carlos Fierro; Howard Schwartz; Kathleen Neuzil; Larry Corey; Peter Gilbert; Holly Janes; Dean Follmann; Mary Marovich; John Mascola; Laura Polakowski; Julie Ledgerwood; Barney S Graham; Hamilton Bennett; Rolando Pajon; Conor Knightly; Brett Leav; Weiping Deng; Honghong Zhou; Shu Han; Melanie Ivarsson; Jacqueline Miller; Tal Zaks
Journal:  N Engl J Med       Date:  2020-12-30       Impact factor: 91.245

8.  Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein.

Authors:  Seth J Zost; Pavlo Gilchuk; Rita E Chen; James Brett Case; Joseph X Reidy; Andrew Trivette; Rachel S Nargi; Rachel E Sutton; Naveenchandra Suryadevara; Elaine C Chen; Elad Binshtein; Swathi Shrihari; Mario Ostrowski; Helen Y Chu; Jonathan E Didier; Keith W MacRenaris; Taylor Jones; Samuel Day; Luke Myers; F Eun-Hyung Lee; Doan C Nguyen; Ignacio Sanz; David R Martinez; Paul W Rothlauf; Louis-Marie Bloyet; Sean P J Whelan; Ralph S Baric; Larissa B Thackray; Michael S Diamond; Robert H Carnahan; James E Crowe
Journal:  Nat Med       Date:  2020-07-10       Impact factor: 87.241

9.  Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2.

Authors:  James Brett Case; Paul W Rothlauf; Rita E Chen; Zhuoming Liu; Haiyan Zhao; Arthur S Kim; Louis-Marie Bloyet; Qiru Zeng; Stephen Tahan; Lindsay Droit; Ma Xenia G Ilagan; Michael A Tartell; Gaya Amarasinghe; Jeffrey P Henderson; Shane Miersch; Mart Ustav; Sachdev Sidhu; Herbert W Virgin; David Wang; Siyuan Ding; Davide Corti; Elitza S Theel; Daved H Fremont; Michael S Diamond; Sean P J Whelan
Journal:  Cell Host Microbe       Date:  2020-07-03       Impact factor: 21.023

10.  Dexamethasone in Hospitalized Patients with Covid-19.

Authors:  Peter Horby; Wei Shen Lim; Jonathan R Emberson; Marion Mafham; Jennifer L Bell; Louise Linsell; Natalie Staplin; Christopher Brightling; Andrew Ustianowski; Einas Elmahi; Benjamin Prudon; Christopher Green; Timothy Felton; David Chadwick; Kanchan Rege; Christopher Fegan; Lucy C Chappell; Saul N Faust; Thomas Jaki; Katie Jeffery; Alan Montgomery; Kathryn Rowan; Edmund Juszczak; J Kenneth Baillie; Richard Haynes; Martin J Landray
Journal:  N Engl J Med       Date:  2020-07-17       Impact factor: 91.245

View more
  7 in total

1.  Convalescent plasma associates with reduced mortality and improved clinical trajectory in patients hospitalized with COVID-19.

Authors:  Shanna A Arnold Egloff; Angela Junglen; Joseph Sa Restivo; Marjorie Wongskhaluang; Casey Martin; Pratik Doshi; Daniel Schlauch; Gregg Fromell; Lindsay E Sears; Mick Correll; Howard A Burris; Charles F LeMaistre
Journal:  J Clin Invest       Date:  2021-10-15       Impact factor: 14.808

Review 2.  Human Identical Sequences, hyaluronan, and hymecromone ─ the new mechanism and management of COVID-19.

Authors:  Shuai Yang; Ying Tong; Lu Chen; Wenqiang Yu
Journal:  Mol Biomed       Date:  2022-05-20

3.  A Novel Method for the Production of an Autologous Anti-Inflammatory and Anti-Catabolic Product (Cytorich) from Human Blood: A Prospective Treatment for the COVID-19-Induced Cytokine Storm.

Authors:  Irina Brokhman; Alyssia M T Watkin; Jeffrey C Bacher; Stephen A Glazer; Anthony M Galea
Journal:  Med Sci Monit       Date:  2021-11-19

4.  Standardized two-step testing of antibody activity in COVID-19 convalescent plasma.

Authors:  Pavlo Gilchuk; Isaac Thomsen; Sandra Yoder; Eric Brady; James D Chappell; Laura J Stevens; Mark R Denison; Rachel E Sutton; Rita E Chen; Laura A VanBlargan; Naveenchandra Suryadevara; Seth J Zost; Jonathan Schmitz; Jill M Pulley; Michael S Diamond; Jillian P Rhoads; Gordon R Bernard; Wesley H Self; Todd W Rice; Allison P Wheeler; James E Crowe; Robert H Carnahan
Journal:  iScience       Date:  2021-12-08

5.  Forty-fifth ASPEN Presidential Address: Research in a pandemic-Why, what, how?

Authors:  Todd W Rice
Journal:  JPEN J Parenter Enteral Nutr       Date:  2021-09-19       Impact factor: 3.896

6.  Neutralizing COVID-19 Convalescent Plasma in Adults Hospitalized With COVID-19: A Blinded, Randomized, Placebo-Controlled Trial.

Authors:  Wesley H Self; Allison P Wheeler; Thomas G Stewart; Harry Schrager; Jason Mallada; Christopher B Thomas; Vince D Cataldo; Hollis R O'Neal; Nathan I Shapiro; Conor Higgins; Adit A Ginde; Lakshmi Chauhan; Nicholas J Johnson; Daniel J Henning; Stuti J Jaiswal; Manoj J Mammen; Estelle S Harris; Sonal R Pannu; Maryrose Laguio-Vila; Wissam El Atrouni; Marjolein de Wit; Daanish Hoda; Claudia S Cohn; Carla McWilliams; Carl Shanholtz; Alan E Jones; Jay S Raval; Simon Mucha; Tina S Ipe; Xian Qiao; Stephen J Schrantz; Aarthi Shenoy; Richard D Fremont; Eric J Brady; Robert H Carnahan; James D Chappell; James E Crowe; Mark R Denison; Pavlo Gilchuk; Laura J Stevens; Rachel E Sutton; Isaac Thomsen; Sandra M Yoder; Amanda J Bistran-Hall; Jonathan D Casey; Christopher J Lindsell; Li Wang; Jill M Pulley; Jillian P Rhoads; Gordon R Bernard; Todd W Rice
Journal:  Chest       Date:  2022-07-01       Impact factor: 10.262

Review 7.  Systematic review and meta-analysis of randomised controlled trials testing the safety and efficacy of convalescent plasma in the treatment of coronavirus disease 2019 (COVID-19): Evidence-base for practise and implications for research.

Authors:  Tejpal Gupta; Sadhana Kannan; Babusha Kalra; Prafulla Thakkar
Journal:  Transfus Med       Date:  2021-06-29       Impact factor: 2.057

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.